Molecular Mechanisms of Normal and Malignant Hematopoiesis: 2nd Edition
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 April 2025 | Viewed by 127
Special Issue Editor
Interests: DNA methylation; TET proteins; hematopoietic stem cells; hematopoiesis; leukemia; cancer epigenetics; cancer therapy; drug screen; metabolic diseases; obesity; diabetes; biosensor; signaling and gene expression
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematopoietic stem cells (HSCs) in the bone marrow ensure lifelong hematopoietic homeostasis by giving rise to the full repertoire of blood cells via highly ordered differentiation processes, while maintaining a proper HSC pool via self-renewal. Recent technological advances, including genome-wide profiling and chromatin analyses, have provided overwhelming evidence that the genetic and epigenetic landscape in hematopoietic stem/progenitor cells changes dynamically during normal hematopoiesis and fate determination, which often becomes impaired under pathological conditions.
Highly heterogeneous genetic mutation profiles are commonly found in various hematopoietic malignancies, some of which can drive oncogenic transformation. In addition, epigenetic factors governing DNA (hydroxy)methylation, histone modifications, nucleosome remodeling, microRNAs, etc., act in concert with diverse transcription factors to tightly control the balance between HSC self-renewal, lineage specification, and differentiation. Chromatin modifiers are considered crucial factors that integrate inputs from the HSC microenvironment or intracellular metabolism with genetic programs to secure normal hematopoiesis. Thus, the aberrant orchestration of genetic and epigenetic mechanisms that disrupts this balance has emerged as a key mechanism that can drive aberrant HSC maintenance and/or function, ultimately leading to various hematologic malignancies, including leukemias and lymphomas. Notably, the reversible nature of epigenetic aberrations makes epigenetic regulators a promising target for the effective treatment of hematologic disorders. Despite significant advances in our understanding of the impact of genetic and epigenetic disruptions on HSC biology and the pathophysiology of hematological malignancies, it still remains challenging to treat these diseases.
For this Special Issue, we invite reviews or original research articles that describe the roles of genetic or epigenetic factors in normal and malignant hematopoiesis. We will also accept articles addressing how hematopoietic cells consolidate inputs from the HSC niche or intracellular metabolism with genetic programs to secure normal HSC self-renewal and differentiation. Topics relevant to the discoveries of novel genetic and epigenetic perturbations, their functional contribution to hematological oncogenesis, and translational studies targeting these aberrations for treating hematological malignancies are also welcomed.
Dr. Myunggon Ko
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematopoietic stem cells
- self-renewal
- differentiation
- hematological malignancies
- molecular mechanisms
- genetic factors
- epigenetic factors
- transcriptional regulation
- HSC niche
- targeted therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
